Message from the Editors-in-Chief

Cardiogenetics is an essential resource for general physicians, cardiologists, and geneticists. Exome sequencing, noncoding DNA, bioinformatics, micro-RNA, long-noncoding DNA and epigenetics have entered our daily vocabulary, highlighting the importance of forming a “cardiogenetics team” working side by side, bringing the lab to the patients’ bed, and vice versa. A strong Editorial Board of active clinicians and scientists will support this new experience. Cardiogenetics publishes high-quality original research papers, review articles, short reports, news and views, with the aim of connecting the scientific (bench) to the clinical (bedside) world. Since 2011, the journal has been increasingly successful. Please help us to overcome this challenge.

Author Benefits

- **Open Access** Unlimited and free access for readers
- **No Copyright Constraints** Retain copyright of your work and free use of your article
- **Thorough Peer-Review**
- **Discounts on Article Processing Charges (APC)** If you belong to an institute that participates with the MDPI Institutional Open Access Program (IOAP)
- **No Space Constraints, No Extra Space or Color Charges** No restriction on the length of the papers, number of figures or colors
- **Rapid Publication** First decision provided to authors approximately 42.2 days after submission; acceptance to publication is undertaken in 5.1 days (median values for papers published in this journal in the first half of 2022).
Aims and Scope

Cardiogenetics (ISSN 2035-8148) is an international, scientific, peer-reviewed, open access journal which provides an advanced forum for studies related to all aspects of cardiogenetics (clinical, molecular, cellular, pharmacological). The journal publishes high-quality original research papers, review articles, short reports, news and views, with the aim of connecting the scientific (bench) to the clinical (bedside) world. As an essential resource for general physicians, cardiologists, and geneticists, Cardiogenetics’ primary purpose is to report original research in the following areas:

- Clinical and molecular aspects of inherited heart diseases (IHDs)
- Clinical and molecular aspects of rare diseases
- Pharmacogenetics and Pharmacogenomics
- Stem cell studies
- Diagnostic methods including sequencing studies
- Bioinformatics and statistical methods in genetics
- Personalized medicine and therapies (gene therapy and gene editing)
- Molecular biology and pathophysiology of genetic and genomic diseases
- Polygenic/multifactorial disorders

A space will be given to negative studies in Cardiogenetics: this space will be dedicated to clinical, molecular, cellular, pharmacological studies, with a solid scientific background, but leading to negative results.